دورية أكاديمية
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model
| العنوان: | Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model |
|---|---|
| المؤلفون: | Shukla,Soham, Shah,Dhvani, Martin,Alan, Risebrough,Nancy A, Kendall,Robyn, Vogelmeier,Claus F, Boucot,Isabelle, Tombs,Lee, Bjermer,Leif, Jones,Paul W, Kerwin,Edward, Compton,Chris, Maltais,François, Lipson,David A, Ismaila,Afisi |
| بيانات النشر: | Dove Press Dove |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | International Journal of Chronic Obstructive Pulmonary Disease, socio |
| الوصف: | Soham Shukla,1 Dhvani Shah,2 Alan Martin,3 Nancy A Risebrough,4 Robyn Kendall,5 Claus F Vogelmeier,6 Isabelle Boucot,3 Lee Tombs,7 Leif Bjermer,8 Paul W Jones,3 Edward Kerwin,9 Chris Compton,3 François Maltais,10 David A Lipson,11,12 Afisi S Ismaila1,13 1Value Evidence and Outcomes, GSK, Collegeville, PA, USA; 2ICON, New York, NY, USA; 3Value Evidence and Outcomes, GSK, Brentford, Middlesex, UK; 4Global Health Economics, and Outcomes Research and Epidemiology, ICON, Toronto, ON, Canada; 5Global Health Economics, and Outcomes Research and Epidemiology, ICON, Vancouver, BC, Canada; 6Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany; 7Precise Approach Ltd, Contingent Worker on Assignment at GSK, Brentford, Middlesex, UK; 8Respiratory Medicine and Allergology, Lund University, Lund, Sweden; 9Altitude Clinical Consulting and Clinical Research Institute of Southern Oregon, Medford, OR, USA; 10Centre de Pneumologie, Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Québec, QC, Canada; 11Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 12Respiratory Clinical Sciences, GSK, Collegeville, PA, USA; 13Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, CanadaCorrespondence: Afisi S IsmailaValue Evidence and Outcomes, GlaxoSmithKline 1250 South Collegeville Road, Collegeville, PA, 19426-0989, USATel +1 919 315 8229Email afisi.s.ismaila@gsk.comIntroduction: Dual bronchodilators are recommended as maintenance treatment for patients with symptomatic COPD in the UK; further evidence is needed to evaluate cost-effectiveness versus monotherapy. Cost-effectiveness of umeclidinium/vilanterol versus umeclidinium and salmeterol from a UK healthcare perspective in patients without exacerbations in the previous year was assessed using post hoc EMAX trial data.Methods: . |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://www.dovepress.com/economic-evaluation-of-umeclidiniumvilanterol-versus-umeclidinium-or-s-peer-reviewed-fulltext-article-COPDTest |
| الإتاحة: | https://www.dovepress.com/economic-evaluation-of-umeclidiniumvilanterol-versus-umeclidinium-or-s-peer-reviewed-fulltext-article-COPDTest |
| حقوق: | undefined |
| رقم الانضمام: | edsbas.E33A76FD |
| قاعدة البيانات: | BASE |
| ResultId |
1 |
|---|---|
| Header |
edsbas BASE edsbas.E33A76FD 857 3 Academic Journal academicJournal 856.820373535156 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.E33A76FD&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://www.dovepress.com/economic-evaluation-of-umeclidiniumvilanterol-versus-umeclidinium-or-s-peer-reviewed-fulltext-article-COPD# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Shukla%2CSoham%22">Shukla,Soham</searchLink><br /><searchLink fieldCode="AR" term="%22Shah%2CDhvani%22">Shah,Dhvani</searchLink><br /><searchLink fieldCode="AR" term="%22Martin%2CAlan%22">Martin,Alan</searchLink><br /><searchLink fieldCode="AR" term="%22Risebrough%2CNancy+A%22">Risebrough,Nancy A</searchLink><br /><searchLink fieldCode="AR" term="%22Kendall%2CRobyn%22">Kendall,Robyn</searchLink><br /><searchLink fieldCode="AR" term="%22Vogelmeier%2CClaus+F%22">Vogelmeier,Claus F</searchLink><br /><searchLink fieldCode="AR" term="%22Boucot%2CIsabelle%22">Boucot,Isabelle</searchLink><br /><searchLink fieldCode="AR" term="%22Tombs%2CLee%22">Tombs,Lee</searchLink><br /><searchLink fieldCode="AR" term="%22Bjermer%2CLeif%22">Bjermer,Leif</searchLink><br /><searchLink fieldCode="AR" term="%22Jones%2CPaul+W%22">Jones,Paul W</searchLink><br /><searchLink fieldCode="AR" term="%22Kerwin%2CEdward%22">Kerwin,Edward</searchLink><br /><searchLink fieldCode="AR" term="%22Compton%2CChris%22">Compton,Chris</searchLink><br /><searchLink fieldCode="AR" term="%22Maltais%2CFrançois%22">Maltais,François</searchLink><br /><searchLink fieldCode="AR" term="%22Lipson%2CDavid+A%22">Lipson,David A</searchLink><br /><searchLink fieldCode="AR" term="%22Ismaila%2CAfisi%22">Ismaila,Afisi</searchLink> ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Dove Press<br />Dove ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2021 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22International+Journal+of+Chronic+Obstructive+Pulmonary+Disease%22">International Journal of Chronic Obstructive Pulmonary Disease</searchLink><br /><searchLink fieldCode="DE" term="%22socio%22">socio</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Soham Shukla,1 Dhvani Shah,2 Alan Martin,3 Nancy A Risebrough,4 Robyn Kendall,5 Claus F Vogelmeier,6 Isabelle Boucot,3 Lee Tombs,7 Leif Bjermer,8 Paul W Jones,3 Edward Kerwin,9 Chris Compton,3 François Maltais,10 David A Lipson,11,12 Afisi S Ismaila1,13 1Value Evidence and Outcomes, GSK, Collegeville, PA, USA; 2ICON, New York, NY, USA; 3Value Evidence and Outcomes, GSK, Brentford, Middlesex, UK; 4Global Health Economics, and Outcomes Research and Epidemiology, ICON, Toronto, ON, Canada; 5Global Health Economics, and Outcomes Research and Epidemiology, ICON, Vancouver, BC, Canada; 6Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany; 7Precise Approach Ltd, Contingent Worker on Assignment at GSK, Brentford, Middlesex, UK; 8Respiratory Medicine and Allergology, Lund University, Lund, Sweden; 9Altitude Clinical Consulting and Clinical Research Institute of Southern Oregon, Medford, OR, USA; 10Centre de Pneumologie, Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Québec, QC, Canada; 11Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; 12Respiratory Clinical Sciences, GSK, Collegeville, PA, USA; 13Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, CanadaCorrespondence: Afisi S IsmailaValue Evidence and Outcomes, GlaxoSmithKline 1250 South Collegeville Road, Collegeville, PA, 19426-0989, USATel +1 919 315 8229Email afisi.s.ismaila@gsk.comIntroduction: Dual bronchodilators are recommended as maintenance treatment for patients with symptomatic COPD in the UK; further evidence is needed to evaluate cost-effectiveness versus monotherapy. Cost-effectiveness of umeclidinium/vilanterol versus umeclidinium and salmeterol from a UK healthcare perspective in patients without exacerbations in the previous year was assessed using post hoc EMAX trial data.Methods: . ) Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => https://www.dovepress.com/economic-evaluation-of-umeclidiniumvilanterol-versus-umeclidinium-or-s-peer-reviewed-fulltext-article-COPD ) Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => https://www.dovepress.com/economic-evaluation-of-umeclidiniumvilanterol-versus-umeclidinium-or-s-peer-reviewed-fulltext-article-COPD ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => undefined ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.E33A76FD ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => International Journal of Chronic Obstructive Pulmonary Disease
[Type] => general
)
[1] => Array
(
[SubjectFull] => socio
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Shukla,Soham
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Shah,Dhvani
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Martin,Alan
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Risebrough,Nancy A
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kendall,Robyn
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Vogelmeier,Claus F
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Boucot,Isabelle
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Tombs,Lee
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Bjermer,Leif
)
)
)
[9] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jones,Paul W
)
)
)
[10] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kerwin,Edward
)
)
)
[11] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Compton,Chris
)
)
)
[12] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Maltais,François
)
)
)
[13] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Lipson,David A
)
)
)
[14] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ismaila,Afisi
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 01
[Type] => published
[Y] => 2021
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-locals
[Value] => edsbas
)
)
)
)
)
)
)
|
| IllustrationInfo |